Loading...
•
Mar 31, 2024
Insmed Q1 2024 Earnings Report
Insmed reported a 16% increase in total revenue, driven by ARIKAYCE sales growth, and shared positive data from TPIP trials.
Key Takeaways
Insmed reported first-quarter 2024 financial results, highlighting a 16% increase in total revenue to $75.5 million compared to Q1 2023. The company is progressing with its ARIKAYCE commercialization and advancing its brensocatib and TPIP clinical programs.
Total revenue for Q1 2024 was $75.5 million, a 16% increase year-over-year.
ARIKAYCE global revenue grew 16% compared to Q1 2023, with growth in the U.S., Japan, and Europe.
Positive topline safety and tolerability data reported from the Phase 2 PH-ILD study of TPIP.
Topline data from the Phase 3 ASPEN trial of Brensocatib is expected in the latter part of Q2 2024.
Insmed
Insmed
Insmed Revenue by Segment
Revenue by Segment
ARIKAYCE U.S. Revenue
CapyFin.comARIKAYCE Japan Revenue
CapyFin.comARIKAYCE Europe & RoW Revenue
CapyFin.com Forward Guidance
Insmed reiterated its full-year 2024 global ARIKAYCE revenue guidance in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally
- Advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis
- Commercial launch readiness activities
- The ongoing Phase 2 trial in patients with CRSsNP
- The Phase 2 program in HS to be initiated in the second half of the year if the ASPEN result is positive
Revenue & Expenses
Visualization of income flow from segment revenue to net income